Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838383 · ClinicalTrials.gov registry record · Phase 2
Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00838383 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 29 participants.
The verdict
NCT00838383, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replacement procedures that require CPB.
Interventions
- DRUG Placebo
- DRUG sitaxsentan (Thelin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-08-10 |
| Est. Completion | 2008-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838383
The ClinicalTrials.gov registry entry for NCT00838383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00838383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838383 about?
NCT00838383 is a clinical study titled "Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery". This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replacement procedures that require CPB.
What is the current status of trial NCT00838383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2006-08-10. Estimated completion is 2008-03-31.
What interventions are being tested in trial NCT00838383?
The interventions under investigation include: Placebo (DRUG), sitaxsentan (Thelin) (DRUG).
Who is sponsoring clinical trial NCT00838383?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.